Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)

NCT07723820 is registered in ClinicalTrials.gov with Thammasat University Hospital as lead sponsor.

NCT NCT07723820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07723820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)
Lead sponsor
Thammasat University Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2027
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic retinopathy (dr), type 2 diabetes mellitus